|
![]() |
|||
|
||||
OverviewThis book provides a practically applicable resource for all clinicians managing patients with or who may develop melanoma. Each chapter focuses on clinically relevant information on the latest advances in the field, including techniques for early detection of skin cancers, cross-sectional imaging and staging of regional nodes. Algorithms for clinical decision-making along with clinical vignettes are incorporated into each chapter, enabling the reader to develop a deep understanding of how to manage a range of scenarios. Practical Manual for Dermatologic and Surgical Melanoma Management systematically details the latest diagnostic criteria, treatment guidelines and management techniques available for treating these patients and is a valuable resource for the trainee and practising clinician. Full Product DetailsAuthor: Delphine J. Lee , Mark B. FariesPublisher: Springer Nature Switzerland AG Imprint: Springer Nature Switzerland AG Edition: 1st ed. 2021 Weight: 0.454kg ISBN: 9783030273996ISBN 10: 3030273997 Pages: 196 Publication Date: 12 May 2020 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: Manufactured on demand ![]() We will order this item for you from a manufactured on demand supplier. Table of ContentsMelanoma Prevention.- Prevention.- Screening.- Racial disparities/melanoma in non-whites with guidelines for all races on screening,-Monitoring (people at-risk, people who have had melanoma-follow up, genetic syndromes, atypical Nevus syndrome), -Primary Melanoma.- Diagnosis.- Prognosis (staging).- Pediatric Melanoma/Spitz Nevi.- Ocular Melanoma.- Mucosal Melanoma.- Treatment of Primary Melanoma.- Mohs Micrographic surgery LMM; role for Immunohistochemistry.- Early stage disease in patients who are not surgical candidates.- Staging (surgeon)/Surgical treatment /Sentinel LN biopsy – when to perform, management of +SLNB.- Adjuvant therapy.- Treatment of Regionally Metastatic Melanoma.- Local therapies for local recurrence (Emanuel) local recurrence/intransit mets.- Management of the positive sentinel Lymph Node.- Radiation therapy.- Metastatic disease.- Targeted therapy (including a section on personalized therapy/genomics).- Immunotherapy (including a section on personalized immune therapies).- Neoadjuvant therapy.- Stage IV surgical management, including M1A, M1B, M1C disease.- Brain metastases.ReviewsThe audience is all physicians caring for melanoma patients or patients who are at high risk for developing melanoma. ... The material is well written and presented in a clear manner. The summary of appropriate studies is concise without being burdensome. ... This is a valuable reference for digesting a huge amount of information on an important topic. (Patricia Wong, Doody's Book Reviews, November 6, 2020) Author InformationDr. Delphine J. Lee is the Chief of Dermatology and Residency Program Director at Harbor-UCLA Medical Center located in the South Bay. She received her MD and PhD at University of California, San Diego and completed her dermatology residency training and postdoctoral fellowship at University of California, Los Angeles. After serving on the faculty at UCLA for five years, she moved to build the Department of Translational Immunology at John Wayne Cancer Institute where her team developed studies utilizing bioinformatic approaches combined with immune studies to gain new insights into melanoma. She currently conducts translational studies on host-microbe associations and interactions in melanoma and other cancers at Los Angeles Biomedical Research Institute and serves as chair and standing member of the NIAMS AMS review committee. Dr. Mark Faries is the Co-Director of the Melanoma Program at the Angeles Clinic and Research Institute and Head of the Surgical Oncology Division. He received his medical degree from Cornell University and completed surgical residency at the University of Pennsylvania. His Fellowship in surgical oncology was at the John Wayne Cancer Institute where he trained under Donald L. Morton. He conducts clinical and translational research in melanoma and immunotherapy and is the Principal Investigator of the Multicenter Selective Lymphadenectomy (II) Trial. He serves on the Editorial Board of of the Annals of Surgical Oncology and is a member of the American Joint Committee on Cancer’s Melanoma Staging Committee. Tab Content 6Author Website:Countries AvailableAll regions |